Key takeaways
- The weight tends to come back. In the semaglutide withdrawal extension, people regained about two-thirds of what they’d lost within a year of stopping, and the trials in tirzepatide show the same pattern.
- This isn’t a willpower failure. The FDA approved these drugs for chronic weight management. Researchers conclude obesity behaves like a long-term condition that needs ongoing treatment, not a 6-month course.
- That makes the real question financial, not medical: can you stay on it? The most common reason people stop isn’t side effects, it’s cost and insurance.
The short answer
If you stop a GLP-1 and change nothing else, most of the weight you lost is likely to return over the following year. That’s not a marketing scare line. It’s the consistent finding across every randomized withdrawal trial run so far, in both semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro).
It’s worth understanding why, because the reason changes how you should plan, and it reframes the most important decision from “which drug” to “how do I afford to stay on the one that works.”
What the withdrawal trials found
The cleanest evidence comes from trials specifically designed to answer this question: take people who’ve already lost weight on the drug, then stop it (or randomly assign some to placebo) and watch what happens.
Semaglutide: about two-thirds regained in one year
In the STEP 1 extension, participants had lost an average of 17.3% of their body weight on semaglutide 2.4 mg over 68 weeks. One year after stopping the drug (and the lifestyle support that came with it), they had regained about two-thirds of that loss, and the improvements in blood pressure, blood sugar, and cholesterol largely reversed alongside the weight.
Source: STEP 1 trial extension, Diabetes, Obesity and Metabolism 2022 (doi:10.1111/dom.14725) · funded by Novo Nordisk, Wegovy's maker (disclosed per our methodology)
The continue-vs-stop comparison (STEP 4)
STEP 4 randomized people who’d already reached the full dose: half kept taking semaglutide, half were switched to placebo. Over the next 48 weeks, the group that continued lost a further 7.9%, while the group switched to placebo regained 6.9%, a 14.8 percentage-point swing that came down entirely to whether they stayed on the drug.
Source: STEP 4 randomized withdrawal trial, JAMA 2021;325(14):1414–1425 · funded by Novo Nordisk
Tirzepatide tells the same story (SURMOUNT-4)
After a 36-week lead-in on tirzepatide, participants were randomized to continue or switch to placebo. Those who continued lost another 5.5%; those who stopped regained 14.0% over the following year. People who stayed on the drug for the full study were down about 25% from where they started; those who stopped ended up around 10%.
Source: SURMOUNT-4 randomized withdrawal trial, JAMA 2024;331(1):38–48 · funded by Eli Lilly, Zepbound's maker
Why it comes back: the part nobody likes
GLP-1 medications work largely by turning down appetite and the body’s “defended” weight set-point while you’re on them. When the drug leaves your system, those signals return to baseline: hunger comes back, and the body’s powerful machinery for regaining lost weight switches back on. This is the same biology that makes weight loss hard to maintain after any method; the drugs don’t switch it off permanently, they hold it at bay.
That’s exactly why the FDA approved Wegovy and Zepbound for chronic weight management. The labels frame them as long-term treatments, the way a blood-pressure pill is. The trial authors put it plainly: their findings “confirm the chronicity of obesity” and show that “ongoing treatment is required to maintain improvements.”
Does it really all come back? The real-world nuance
Two real caveats keep this from being the whole story.
Regain may be more gradual in real life than in the trials. The withdrawal trials stopped the drug abruptly under study conditions. Real-world data from a large Cleveland Clinic cohort suggests that outside a trial, weight tends to drift back more slowly, but the direction is the same: without continued treatment, the trend is back toward baseline.
Staying on it is what separates good outcomes from disappointing ones. That same real-world study of nearly 8,000 patients found the gap starkly:
One-year results, by whether people kept taking it
At one year, people who stayed on semaglutide or tirzepatide were down 11.9%. Those who stopped early were down just 3.6%. Continuity of treatment, not which drug, was the single biggest driver of who kept the weight off.
Source: Gasoyan H et al., Obesity 2025 (doi:10.1002/oby.24331); Cleveland Clinic cohort, 7,881 adults
So the real question is: can you stay on it?
Here’s the uncomfortable reframe. If the evidence says results depend on staying on the medication, then the make-or-break factor isn’t tolerability or even which GLP-1 you pick: it’s whether you can keep affording and accessing it. And in the patient communities we track, the loudest reason people stop isn’t nausea. It’s a denied prior authorization, a formulary change, or a price increase.
That means two things are worth doing before you’re forced to stop:
If you have a cardiovascular history, there’s an added reason continuity matters: semaglutide’s heart-protective benefit (about a 20% reduction in major cardiac events in the SELECT trial) also depends on staying on treatment. That’s a conversation worth having with your prescriber.
Why we recommend them: the highest score in our independent rubric for insurance and prior-authorization support, the factor that most determines whether people can keep their results. We take no money from Form Health; the link goes to their own site.
If you and your doctor do decide to stop
Stopping isn’t always the wrong call. People pause for pregnancy planning, side effects, cost, or because they’ve reached a maintenance plan with their clinician. If you do:
- Do it with your prescriber, not on your own. Some clinicians taper the dose or move to a lower maintenance dose rather than stopping cold.
- Lock in habits beforehand. Resistance training and adequate protein won’t fully override the biology, but the people who maintain best tend to have those in place before they stop.
- Expect appetite to return first. Rising hunger is the early signal: it’s physiology, not a personal failing. Knowing it’s coming makes it easier to plan around.
- Re-starting is normal and effective. Regain doesn’t mean the drug “stopped working.” If you restart, it generally works again.
Frequently asked questions
Will I regain all the weight if I stop?
Not necessarily all of it, but the trials show most people regain a substantial share, about two-thirds in the year after stopping semaglutide, with a similar pattern for tirzepatide. How much you keep off depends heavily on whether you maintain the habits built while on the drug, and many people ultimately need some form of ongoing treatment.
Is there a 'maintenance dose' I can drop down to instead of stopping?
Some clinicians use a lower maintenance dose rather than full discontinuation, and this is an active area of research. There’s no one-size-fits-all answer yet: it’s a decision to make with your prescriber based on how you respond.
Why does insurance only cover it for a limited time?
Many plans approve GLP-1s in increments and require re-authorization, and some drop coverage after a period or a weight target. Because the evidence shows stopping leads to regain, a coverage cutoff is often where people lose their progress, which is exactly what an appeal can address. See our free appeal letter templates.
Does the weight come back faster than it came off?
In the controlled withdrawal trials, regain happened over roughly a year, gradually, not overnight. Real-world data suggests it may be even more gradual outside a trial. The consistent finding is the direction (back toward baseline), not a cliff.
- STEP 1 trial extension. Wilding JPH et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism 2022;24(8):1553–1564 (doi:10.1111/dom.14725; PMID 35441470). One year after stopping semaglutide 2.4 mg, participants regained about two-thirds of the weight they had lost. Funded by Novo Nordisk (Wegovy's manufacturer).
- STEP 4 randomized withdrawal trial. Rubino D et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance, JAMA 2021;325(14):1414–1425. After a 20-week run-in, continuing semaglutide produced a further −7.9% over weeks 20–68, versus +6.9% regain when switched to placebo (−14.8 percentage-point difference). Funded by Novo Nordisk.
- SURMOUNT-4 randomized withdrawal trial. Aronne LJ et al., Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity, JAMA 2024;331(1):38–48. After a 36-week lead-in, continuing tirzepatide added −5.5% more weight loss versus +14.0% regain on placebo over the next 52 weeks. Funded by Eli Lilly (Zepbound's manufacturer).
- Real-world cohort. Gasoyan H et al., Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status, Obesity 2025 (doi:10.1002/oby.24331); Cleveland Clinic electronic-health-record cohort, 7,881 adults. One-year weight change was −11.9% for those who stayed on treatment vs −3.6% for early discontinuers.
- FDA prescribing information: Wegovy (semaglutide), Zepbound (tirzepatide): both are indicated for chronic (long-term) weight management.
This article was produced using our 31-point scoring methodology; every primary source we cite across the site is collected in our consolidated bibliography. We analyze published research and consumer reviews; we do not personally test medical products. This is not medical advice. Consult a licensed clinician.